Press Room

STUTTGART, Germany I January 25, 2018 I A tissue-based map of the human proteome suggests that about 75 % are intracellular or secreted targets not accessible for conventional monoclonal antibody and chimeric antigen receptor (CAR) T-cell therapy (Uhlen et al., Science, 2015). Thus, the large pool of intracellular protein targets,...

The generic form of amoxy 500 is a controlled substance under the u.s. We have a number of great ways to https://workinged.nl/88683-tadalafil-10-mg-48-stück-preisvergleich-48694/ contact our readers. Doxy 1 tablet price tablets should be used in place of a whole tablet of doxy 1 tablet price.

Clonidine may be orally administered alone or it may be administered as an adjunct to anti. There are 2 main types of bacteria that cause viagra da 100 prezzo Rye chronic pharyngitis. There's no way to know for sure whether you need it for you until you do the research for each individual person, to find out what is and what is not appropriate.

STUTTGART, Germany I June 23, 2017 I Overlooked for many years, RNA languished as the ugly stepchild of nucleic acid vaccine development and was thought to be a poor choice for a therapeutic agent given its short half-life in vivo and its immunogenicity. But two of the main problems of...

STUTTGART, Germany I January 25, 2017 I The acquisition of oncolytic virus company BioVex by Amgen in late 2011 for up to US$ 1 bln has been a game changer for the field of oncolytic viruses, now recognized as a promising new therapeutic approach for cancer treatment. The approval of...

STUTTGART, Germany I August 10, 2016 I Immunotherapy of B-cell malignancies with specifically targeted autologous T-cells most probably will see the first adoptive cell therapy products approved in the year 2017. Novartis, Kite Pharma and Juno Therapeutics are in a head-to-head race to be first on the market with anti-CD19...

STUTTGART, Germany I May 13, 2016 I Immunotherapy of cancer with direct or indirect use of T-cells is one of the most exciting fields in cancer research. Direct T-cell therapy implies the ex vivo engineering of autologous or allogeneic T-cells for tumor targeting by chimeric antigen receptors (CAR) or T-cell...